Phaseline

Targets › FTH1

FTH1 (Ferritin heavy chain): drug programs, companies and trials

6 programs from 5 companies in 6 trials: 3 Phase 4, 3 Phase 3; Hematology, Genitourinary, Neurology; next expected readout Oct 2027.

Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. (UniProt, P02794)

Open in Phaseline: the race on FTH1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Children's Hospital Los AngelesNovaFerrum
Iron replacement via polymaltose complex
FTH1Phase 4IDA - Iron Deficiency AnemiaSep 2028
Weill Medical College of Cornell UniversityFerrous Sulfate
Iron supplementation; elemental iron repletes iron stores and supports hemoglobin synthesi
FTH1Phase 4Chronic Kidney InsufficiencyDec 2028
Oregon Health and Science UniversityIron-Dextran Complex Injection [InFed]
Iron replacement therapy for iron-deficiency anemia
HMOX1, FTH1Phase 4Acute Blood Loss Anemia–
Hull University Teaching Hospitals NHS TrustFerrous Sulfate
Oral iron supplementation for iron deficiency anemia
FTH1Phase 3Peritoneal DialysisOct 2027
Hull University Teaching Hospitals NHS TrustMonofer (iron isomaltoside 1000)
Intravenous iron supplementation for iron deficiency anemia
FTH1Phase 3Peritoneal DialysisOct 2027
The George InstituteDeferoxamine Mesylate
Iron chelator that reduces iron-mediated oxidative stress and secondary brain injury from
IRE1, FTH1Phase 3Intracerebral HemorrhageJan 2028

Conditions

Peritoneal Dialysis (2) IDA - Iron Deficiency Anemia (1) Chronic Kidney Insufficiency (1) Intracerebral Hemorrhage (1) Acute Blood Loss Anemia (1)

Modalities

small molecule (6)

Companies

Hull University Teaching Hospitals NHS Trust (2) Children's Hospital Los Angeles (1) Weill Medical College of Cornell University (1) The George Institute (1) Oregon Health and Science University (1)

Related targets

IRE1 (1) HMOX1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.